---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-016864"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:57:15.480436+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma Q3 net loss $16M, pipeline advances with SkinJect and Teverelix

## Summary
- Net loss $16.0M in Q3 2025 vs $2.3M in Q3 2024; R&D $1.7M, G&A $5.0M.
- Cash $8.7M at Sep 30, 2025, up from $5.3M; raised $10.4M from financings and warrant exercises.
- Phase 2 SKNJCT-003 >75% enrolled; FDA Type C meeting supports 505(b)(2) pathway for D-MNA (BCC).
- Completed Antev acquisition (Teverelix, GnRH antagonist) in August 2025; UK approvals for SKNJCT-003 expansion.
- Strategic collaboration with Gorlin Syndrome Alliance for expanded access to SkinJect under FDA IND.

## SEC filing metadata
- accession: 0001062993-25-016864
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325016864/0001062993-25-016864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325016864/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-016864
- JSON: https://secwatch.observer/filing/0001062993-25-016864.json
- Plain text: https://secwatch.observer/filing/0001062993-25-016864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.